Simbrinza, a 1.0 percent brinzolamide and 0.2 percent brimonidine tartrate suspension, has proven to decrease intraocular pressure by 21 to 35 percent.
Alcon’s glaucoma therapy is currently the only fixed-dose combination without a beta blocker to be offered in the U.S.
More Articles on Ophthalmology:
Twin Falls Vision Clinic Expands, Recruits Dr. Kyle Klingler
3 Statistics on Cataract Surgery Procedure Times in ASCs
Bausch + Lomb, Leica Microsystems Make Global Distributing Agreement
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
